434 related articles for article (PubMed ID: 11860706)
1. Immunoinhibitory DNA vaccine protects against autoimmune diabetes through cDNA encoding a selective CTLA-4 (CD152) ligand.
Prud'homme GJ; Chang Y; Li X
Hum Gene Ther; 2002 Feb; 13(3):395-406. PubMed ID: 11860706
[TBL] [Abstract][Full Text] [Related]
2. A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity.
Chakrabarti R; Zhou ZF; Chang Y; Prud'homme GJ
Vaccine; 2005 Aug; 23(37):4553-64. PubMed ID: 15919138
[TBL] [Abstract][Full Text] [Related]
3. Protective regulatory T cell generation in autoimmune diabetes by DNA covaccination with islet antigens and a selective CTLA-4 ligand.
Glinka Y; Chang Y; Prud'homme GJ
Mol Ther; 2006 Oct; 14(4):578-87. PubMed ID: 16790365
[TBL] [Abstract][Full Text] [Related]
4. T cells of staphylococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this co-stimulatory signal.
Zhou T; Weaver C; Linsley PS; Mountz JD
Eur J Immunol; 1994 May; 24(5):1019-25. PubMed ID: 7514125
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic T lymphocyte antigen 4 (CD152) regulates self-reactive T cells in BALB/c but not in the autoimmune NOD mouse.
Piganelli JD; Poulin M; Martin T; Allison JP; Haskins K
J Autoimmun; 2000 Mar; 14(2):123-31. PubMed ID: 10677243
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist.
Fife BT; Griffin MD; Abbas AK; Locksley RM; Bluestone JA
J Clin Invest; 2006 Aug; 116(8):2252-61. PubMed ID: 16886063
[TBL] [Abstract][Full Text] [Related]
7. Low CD86 expression in the nonobese diabetic mouse results in the impairment of both T cell activation and CTLA-4 up-regulation.
Dahlén E; Hedlund G; Dawe K
J Immunol; 2000 Mar; 164(5):2444-56. PubMed ID: 10679081
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse.
Lenschow DJ; Ho SC; Sattar H; Rhee L; Gray G; Nabavi N; Herold KC; Bluestone JA
J Exp Med; 1995 Mar; 181(3):1145-55. PubMed ID: 7532678
[TBL] [Abstract][Full Text] [Related]
9. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation.
Salomon B; Bluestone JA
Annu Rev Immunol; 2001; 19():225-52. PubMed ID: 11244036
[TBL] [Abstract][Full Text] [Related]
10. Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4.
Horspool JH; Perrin PJ; Woodcock JB; Cox JH; King CL; June CH; Harlan DM; St Louis DC; Lee KP
J Immunol; 1998 Mar; 160(6):2706-14. PubMed ID: 9510170
[TBL] [Abstract][Full Text] [Related]
11. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA
J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249
[TBL] [Abstract][Full Text] [Related]
12. Interference with CD28, CD80, CD86 or CD152 in collagen-induced arthritis. Limited role of IFN-gamma in anti-B7-mediated suppression of disease.
Tellander AC; Pettersson U; Runström A; Andersson M; Michaëlsson E
J Autoimmun; 2001 Aug; 17(1):39-50. PubMed ID: 11488636
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory effects of a plasmid expressing B7-2 on human immunodeficiency virus-1-specific cell-mediated immunity induced by a plasmid encoding the viral antigen.
Tsuji T; Hamajima K; Ishii N; Aoki I; Fukushima J; Xin KQ; Kawamoto S; Sasaki S; Matsunaga K; Ishigatsubo Y; Tani K; Okubo T; Okuda K
Eur J Immunol; 1997 Mar; 27(3):782-7. PubMed ID: 9079822
[TBL] [Abstract][Full Text] [Related]
14. Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses.
Roy M; Aruffo A; Ledbetter J; Linsley P; Kehry M; Noelle R
Eur J Immunol; 1995 Feb; 25(2):596-603. PubMed ID: 7533092
[TBL] [Abstract][Full Text] [Related]
15. Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells.
Lazetic S; Leong SR; Chang JC; Ong R; Dawes G; Punnonen J
J Biol Chem; 2002 Oct; 277(41):38660-8. PubMed ID: 12167647
[TBL] [Abstract][Full Text] [Related]
16. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.
Vandenborre K; Van Gool SW; Kasran A; Ceuppens JL; Boogaerts MA; Vandenberghe P
Immunology; 1999 Nov; 98(3):413-21. PubMed ID: 10583602
[TBL] [Abstract][Full Text] [Related]
17. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
Carreno BM; Bennett F; Chau TA; Ling V; Luxenberg D; Jussif J; Baroja ML; Madrenas J
J Immunol; 2000 Aug; 165(3):1352-6. PubMed ID: 10903737
[TBL] [Abstract][Full Text] [Related]
18. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.
Linsley PS; Greene JL; Tan P; Bradshaw J; Ledbetter JA; Anasetti C; Damle NK
J Exp Med; 1992 Dec; 176(6):1595-604. PubMed ID: 1334116
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with glutamic acid decarboxylase plasmid DNA protects mice from spontaneous autoimmune diabetes and B7/CD28 costimulation circumvents that protection.
Balasa B; Boehm BO; Fortnagel A; Karges W; Van Gunst K; Jung N; Camacho SA; Webb SR; Sarvetnick N
Clin Immunol; 2001 May; 99(2):241-52. PubMed ID: 11318596
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2).
Morton PA; Fu XT; Stewart JA; Giacoletto KS; White SL; Leysath CE; Evans RJ; Shieh JJ; Karr RW
J Immunol; 1996 Feb; 156(3):1047-54. PubMed ID: 8557978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
